Melli Manizheh Sayyah, Farzadi Laya, Madarek Elaheh O S
Department of Obstetrics and Gynecology, Alzahra Hospital, South Artesh Avenue, Tabriz, Iran.
Saudi Med J. 2007 Mar;28(3):445-50.
To investigate the effect of cabergoline (Dostinex, a dopamine agonist) on the myoma growth compared to Diphereline (a gonadotropin-releasing hormone agonist).
This study took place in the Department of Obstetrics and Gynecology of Tabriz University of Medical Sciences, Tabriz, Iran from July 2004 to December 2005. Fifty women with uterine myoma, who met the criteria of the study thoroughly, were randomly allocated into 2 equal groups to take either Diphereline or Cabergoline. The first Group took 3.75 mg of Diphereline 4 times every 28 days and the second group took 0.5 mg of Cabergoline once a week for 6 weeks.
The Cabergoline was well tolerated and fewer adverse effects were noted. The tumor regressed significantly and volume reduction rate of individual tumor nodule varied from 46-53%. The gonadotropin releasing hormone agonist group all responded to the treatment, and volume reduction rate of the individual tumor nodule varied from 21-97%. The extent of tumor shrinkage was positively correlated to the number of nodules (p=0.881, p<0.005 and 0.701, p<0.005).
In light of therapeutic efficacy and few adverse effects, the dopamine agonists may hold promise as novel treatment modalities for leiomyoma. Further studies are warranted to determine the optimal strategy for the treatment of leiomyoma through these agents.
与达必佳（一种促性腺激素释放激素激动剂）相比，研究卡麦角林（多喜，一种多巴胺激动剂）对肌瘤生长的影响。
本研究于2004年7月至2005年12月在伊朗大不里士医科大学妇产科进行。50名完全符合研究标准的子宫肌瘤女性被随机分为两组，分别服用达必佳或卡麦角林。第一组每28天注射3.75毫克达必佳，共4次；第二组每周服用0.5毫克卡麦角林，持续6周。
卡麦角林耐受性良好，不良反应较少。肿瘤明显消退，单个肿瘤结节体积缩小率在46%-53%之间。促性腺激素释放激素激动剂组均对治疗有反应，单个肿瘤结节体积缩小率在21%-97%之间。肿瘤缩小程度与结节数量呈正相关（p=0.881，p<0.005；以及p=0.701，p<0.005）。
鉴于其治疗效果及较少的不良反应，多巴胺激动剂有望成为子宫肌瘤的新型治疗方式。有必要进一步开展研究以确定通过这些药物治疗子宫肌瘤的最佳策略。
